HOME >> BIOLOGY >> NEWS
Stronger evidence found linking Epstein-Barr virus and risk of multiple sclerosis

Boston, MA Researchers from the Harvard School of Public Health, Kaiser Permanente, and a team of collaborators have found further evidence implicating the Epstein-Barr virus (EBV) as a possible contributory cause to multiple sclerosis (MS). The study appears in the advance online edition of the June 2006 issue of Archives of Neurology.

MS is a chronic degenerative disease of the central nervous system. Women are more likely than men to get the disease and it is the most common neurologically disabling disease in young adults. Although genetic predisposition plays an important role in determining susceptibility, past studies have shown that environmental factors are equally important.

EBV is a herpes virus and one of the most common human viruses worldwide. Infection in early childhood is common and usually asymptomatic. Late age at infection, however, often causes infectious mononucleosis. In the U.S., upwards of 95% of adults are infected with the virus, but free of symptoms. EBV has been associated with some types of cancer and can cause serious complications when the immune system is suppressed, for example, in transplant recipients. There is no effective treatment for EBV.

The study population was made up of more than 100,000 members of the Kaiser Permanente Northern California (KPNC) health plan, who provided blood specimens as part of medical examinations between 1965 and 1974. The KPNC maintained the medical records of all its members, including those who provided specimens, in electronic databases. Between 1995 and 1999, those databases were searched for evidence that would indicate a possible diagnosis of MS.

The researchers selected 42 individuals diagnosed with MS and that had serum specimens collected before the date of diagnosis. Two controls for each case were then selected from the serum database and matched by sex, date of blood collection, and age at time of blood collection.

The study's main finding was th
'"/>

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-3952
Harvard School of Public Health
11-Apr-2006


Page: 1 2 3

Related biology news :

1. Stronger therapy better for AML with normal genetics
2. No evidence that widely prescribed statins protect against prostate cancer
3. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
4. CU researchers discover evidence of very recent human adaptation
5. Research finds evidence tropical cyclones have climate-control role
6. New evidence of human culture among primates
7. Study advances evidence for receptors role in alcohol pleasure and problems
8. Study provides first genetic evidence of long-lived African presence within Britain
9. More human-Neandertal mixing evidence uncovered
10. First evidence to show elephants, like humans, apes and dolphins, recognize themselves in mirror
11. New MUHC study adds more evidence to clear measles mumps rubella vaccine as a risk factor for autism

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first ... insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and ... be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), ... Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global ... of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of ... located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, ... its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes at ... requiring fast track capacity to provide patients with urgently needed vaccines and other ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter ... great surgery is only the beginning of a successful study, while protecting and accessing ... Brad Gien, Global Head of Surgery from Envigo in a live ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, a ... laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume ... Bode-CARES provides a turnkey solution that includes a comprehensive collection and virus-management ...
Breaking Biology Technology:
Cached News: